Published on in Vol 8, No 10 (2021): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/31173, first published .
A Personalized, Interactive, Cognitive Behavioral Therapy–Based Digital Therapeutic (MODIA) for Adjunctive Treatment of Opioid Use Disorder: Development Study

A Personalized, Interactive, Cognitive Behavioral Therapy–Based Digital Therapeutic (MODIA) for Adjunctive Treatment of Opioid Use Disorder: Development Study

A Personalized, Interactive, Cognitive Behavioral Therapy–Based Digital Therapeutic (MODIA) for Adjunctive Treatment of Opioid Use Disorder: Development Study

Journals

  1. Ryan K, Prewitt K, Hayer S, Hedges M, Benson A, Lo J. Opioid Use in Pregnancy: A Review. Obstetrical & Gynecological Survey 2023;78(1):35 View
  2. Ning A, Csiernik R. Canadian government discourses on the overdose death crisis: limitations of a bio-evidenced approach. Drugs, Habits and Social Policy 2022;23(1):62 View
  3. Jeon E, Yoon N, Sohn S. Exploring new digital therapeutics technologies for psychiatric disorders using BERTopic and PatentSBERTa. Technological Forecasting and Social Change 2023;186:122130 View
  4. Ning A, Csiernik R. Why has the Opioid Crisis Remained Unchanged in Canada? The Limits of Bio-Scientific Based Policy Approaches. Journal of Social Work Practice in the Addictions 2024;24(1):1 View
  5. Abbasi M, Golmohammadian M, Kakabraee K. Enhancing Psychological Hardiness and Distress Tolerance in Mothers of Hard of Hearing Children: The Efficacy of Mindfulness Integrated with Spiritual Therapy. Journal of Clinical Research in Paramedical Sciences 2023;12(2) View
  6. Sawyer-Morris G, Wilde J, Molfenter T, Taxman F. Use of Digital Health and Digital Therapeutics to Treat SUD in Criminal Justice Settings: a Review. Current Addiction Reports 2023;11(1):149 View
  7. Al Faysal J, Noor-E-Alam M, Young G, Lo-Ciganic W, Goodin A, Huang J, Wilson D, Park T, Hasan M. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals. Computers in Biology and Medicine 2024;177:108493 View